Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2008

2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

ABLYNX Reports Positive Phase Ib Results for its Anti-Thrombotic NANOBODY® ALX-0081

December 12, 2008 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its anti-thrombotic ALX-0081, has reached the primary endpoint of the current Phase Ib study,…

Related to: Ablynx

Agendia’s MammaPrint® Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

December 12, 2008 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS — Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint®’s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van ‘t Veer, from the Netherlands Cancer Institute, presented…

Related to: Agendia

CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat

December 11, 2008 – Oxford – Chroma Therapeutics Limited, a leading European specialist cancer research company, announced today positive data from a Phase II study with its oral, once-daily experimental cancer therapy tosedostat (CHR-2797) in the treatment of patients with acute myeloid leukemia (AML)…

Related to: Chroma Therapeutics

ABLYNX Reaches Milestone in TNF-alpha NANOBODY® Collaboration

December 10, 2008 – Ghent, Belgium – Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has reached a milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a…

Related to: Ablynx

Agendia Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

December 8, 2008 – Huntington Beach, CA, and AMSTERDAM, THE NETHERLANDS -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium…

Related to: Agendia

ABLYNX Expands its Anti-Thrombotic Portfolio and Announces Initiation of a Phase I Study for ALX-068

December 8, 2008 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has initiated a double-blind, randomized, placebo-controlled Phase I study in healthy volunteers…

Related to: Ablynx

Symphogen receives milestone payment from Meiji Seika Kaisha

December 4, 2008 – SYMPHOGEN AND MEIJI SEIKA KAISHA LTD. ACHIEVE MILESTONE IN DISCOVERY COLLABORATION FOR RECOMBINANT POLYCLONAL ANTIBODY, SYM006 COPENHAGEN, Denmark and TOKYO, Japan – Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the…

Related to: Symphogen

Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers

December 1, 2008 – Results will be discussed at the European Antibody Congress in Geneva, December 2 and at the IBC’s International Conference on Antibody Engineering in San Diego, December 11. Copenhagen, Denmark – Symphogen A/S today announced that John Haurum, Chief Scientific Officer and Michael…

Related to: Symphogen

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

November 20, 2008 – STOCKHOLM, Sweden and COPENHAGEN, Denmark – Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN)…

Related to: Symphogen

IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®

November 5, 2008 – Munich, Germany – IDEA AG has recently presented results of a US phase III, 12-month clinical safety and efficacy study of Diractin® (ketoprofen in Transfersome® gel, formerly known as IDEA-033) in patients with osteoarthritis of both knees in comparison to oral naproxen (Study CL-033-III-05)…

Related to: IDEA

INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights

October 6, 2008 – Novo Nordisk A/S (“NN”) and Innate Pharma (“IPH”) have reached an agreement by which IPH is granted full development and commercial rights to IPH 2101 in exchange of full rights to IPH 2301 plus 2.5 million euros upfront payment, milestone payments and royalties on future sales of…

Related to: Innate Pharma

AMT intends to incorporate additional data to its Marketing Authorization Dossier for Glybera®

October 3, 2008 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it intends to incorporate additional data into the Marketing Authorization Application (MAA) for Glybera® for Lipoprotein Lipase Deficiency…

Acacia Pharma Starts First Clinical Trial with APD 405 for Nausea & Vomiting

September 22, 2008 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, has initiated its first clinical trial, a Phase I study of its lead product candidate APD 405. Acacia is one of the few companies focused on supportive care, especially…

Related to: Acacia Pharma

AMT Obtains License to Amgen’s GDNF Gene to Develop Treatment for Parkinson’s Disease

September 18, 2008 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson’s disease. The combination…

Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines

September 18, 2008 – HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare…

Related to: Agendia

ABLYNX and Merck Serono Enter into an Agreement to Co-Discover and Co-Develop NANOBODIES®

September 4, 2008 – Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits Ghent, BELGIUM - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a…

Related to: Ablynx

Agendia Launches TargetPrint for Breast Cancer Patients

September 4, 2008 – HUNTINGTON BEACH, CA, and AMSTERDAM, The Netherlands / Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint®, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor…

Related to: Agendia

IDEA AG gives an update on the development of Diractin®, the targeted analgesic

July 29, 2008 – Munich, Germany – IDEA AG today publicised two additional phase III clinical studies with Diractin® (ketoprofen in Transfersome® carriers, formerly known as IDEA-033) and successful completion of two long-term studies with the product. In Q2 2008, IDEA started screening and enrolment…

Related to: IDEA

BG MEDICINE Announces Publication of Biomarker Signature of Atherosclerotic Plaque Rupture

July 24, 2008 – Waltham, Mass., BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel diagnostics, today announced the publication* of the biomarker discovery study yielding its novel diagnostic candidate for the detection of ruptured plaque, the…

Related to: BG Medicine

BG Medicine Closes $40 Million in Series D Financing

July 17, 2008 – Funds to accelerate launch of diagnostic products to enable Biomarker-Guided Medicine  Waltham, Mass., BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and…

Related to: BG Medicine

PIERIS - Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology

July 16, 2008 – FREISING-WEIHENSTEPHAN and JENA, Germany, July 16 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, and Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, announced today…

Related to: Pieris Pharmaceuticals Inc.

SYMPHOGEN and BIOVITRUM have Initiated a Novel Treatment Study in Autoimmune Bleeding Disorder (ITP)

July 16, 2008 – COPENHAGEN, Denmark and STOCKHOLM, Sweden – Symphogen A/S and Biovitrum AB (publ) (STO:BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic…

Related to: Symphogen

AGENDIA and FERRER announces exclusive agreement for sales of cancer diagnostic services in four maj

July 15, 2008 – AMSTERDAM, The Netherlands and BARCELONA, Spain - Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia’s signature cancer diagnostic services. MammaPrint, a prognostic test that uses a 70-gene signature to indicate…

Related to: Agendia

Santaris Pharma Appoints Søren Tulstrup as New President & CEO

June 19, 2008 – Santaris Pharma A/S, the Danish biopharmaceutical company, announced today that Søren Tulstrup, previously Vice President, Global Human Health at Merck & Co., Inc., has been appointed President & Chief Executive Officer, effective July 1, 2008. He takes over as CEO from Dr. Keith…

Related to: Santaris Pharma

FlowCardia, Inc. Appoints Deborah DeFilippo CFO

June 18, 2008 – SUNNYVALE, Calif., June 18, 2008 -- FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer.…

Related to: Flowcardia

AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera®)

June 13, 2008 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has concluded enrollment and treated the last patient in the pivotal trial for it’s lead product AMT-011 (Glybera®) for Hyperlipoproteinemia,…

Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics in Infectious

June 11, 2008 – Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.  In this collaboration, Symphogen will apply its proprietary Symplex(TM) antibody discovery…

Related to: Symphogen

AMT makes important advance in the development of its gene therapy for Hemophilia B

June 10, 2008 – Company Accesses Technology to Prevent Immune Response Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from ‘TIGET’ San Raffaele Telethon Institute For Gene Therapy,…

AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011

May 30, 2008 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that positive interim data from its pivotal clinical trial with AMT's lead product Glybera® (AMT-011) were presented by the Principal Investigator,…

AMT’s Cooperative Research and Development Agreement with NIH to Boost Production Capacity

May 26, 2008 – Production Increase Brings Large Disease Areas within Reach Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a Cooperative Research and Development Agreement from the National…

AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

May 22, 2008 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from La Sapienza University in Rome, Italy, to their advanced small nuclear RNA (snRNA)-based exon-skipping technology…

Agendia’s lead product MammaPrint® receives important award from Innovation Platform

May 16, 2008 – Amsterdam - MammaPrint® can reduce the use of chemotherapy in breast cancer treatment by a quarter Agendia’s MammaPrint® has been declared one of the four most pioneering healthcare innovations by the Dutch Innovation Platform. At the Healthcare summit, Minister Klink, chairman of…

Related to: Agendia

IDEA AG receives two milestone payments ($37 million) from partner Alpharma

May 7, 2008 – IDEA AG today announced that it has received two milestone payments under the US licensing agreement with Alpharma Ireland Limited for Diractin® (ketoprofen in Transfersome®, formerly known as IDEA-033). The total payment of $37 million was triggered by IDEA's reaching clinical as…

Related to: IDEA

Symphogen and Biovitrum Initiate a Second Clinical study with a Novel Treatment of Hemolytic Disease

April 15, 2008 – STOCKHOLM, Sweden and COPENHAGEN, Denmark – Biovitrum AB (publ) (Ticker: STO:BVT) and Symphogen A/S today announced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation…

Related to: Symphogen

BG Medicine announces collaboration with Takeda to Discover Biomarkers of High-Risk Atherosclerotic

April 1, 2008 – Boston – BG Medicine, on behalf of the HRP Initiative, today announced that Takeda Pharmaceutical Company Limited (“Takeda”) has joined BG Medicine, Merck, AstraZeneca, and Philips as the newest member of the Initiative. The HRP Initiative is a pre-competitive industry collaboration…

Related to: BG Medicine

Pieris Raises EUR 25 million in Series B Financing Round

March 27, 2008 – FREISING-WEIHENSTEPHAN, Germany - Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor OrbiMed Advisors LLC, a major global fund dedicated…

Related to: Pieris Pharmaceuticals Inc.

Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer

March 25, 2008 – SAN DIEGO, /PRNewswire/ - Conatus Pharmaceuticals Inc. today announced the appointment of Anthony "Tony" W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the…

Related to: Conatus Pharmaceuticals

ABLYNX Receives Milestone Payment from NANOBODY® Discovery and Development Alliance

February 19, 2008 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has received an undisclosed milestone payment from Novartis for an exclusive research license…

Related to: Ablynx

Gilde Healthcare Partners awarded European Venture Fundraising of the year

February 12, 2008 – Utrecht – Gilde Healthcare Partners, a rapidly growing European venture capital firm, has received the Venture Fundraising of the Year Award from the European Venture Capital Journal. The Award was for the successful closing of Gilde Healthcare II (GHC II), its EUR 150 million venture…

BG Medicine and Copenhagen General Population Study Initiate Biomarker Discovery

February 12, 2008 – Danish population study offers opportunity for discovery of blood biomarkers in individuals who suffer a heart attack without prior history of cardiovascular disease. BG Medicine today announced that it has entered into a research collaboration agreement with the Copenhagen General…

Related to: BG Medicine

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial

February 6, 2008 – Biovitrum and Symphogen are developing a recombinant, polyclonal antibody (Sym001) for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and prophylaxis of rhesus hemolytic disease of the newborn. The phase I clinical trial was initiated in March 2007 and the results from…

Related to: Symphogen

BG Medicine Acquires Exclusive Commercial Rights to Biomarker of Vascular Plaque Rupture

February 5, 2008 – BG Medicine plans to develop and commercialize diagnostic tests to aid in early diagnosis of acute cardiac and cerebral disorders Waltham, Mass. and Maastricht, The Netherlands. BG Medicine, Inc. (BG Medicine) and ACS Biomarker B.V. (ACS Biomarker) today announced that they have…

Related to: BG Medicine

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing EUR 1 billion (USD 1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy